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Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome (PRO) Measures: Summary of an 
FDA and Critical Path Institute Workshop 
 
ABSTRACT 
Objective: The U.S. Food and Drug Administration and the Critical Path Institute ?Ɛ PRO Consortium convened a co-
sponsored workshop on the use of patient-reported outcome (PRO) measures to inform the assessment of safety 
and tolerability in cancer clinical trials.  
Study Design: Open Public Workshop 
Methods: A broad array of international stakeholders involved in oncology product development and PRO 
measurement science provided perspectives on the role of PRO measures to provide complementary clinical data 
on the symptomatic side effects of anti-cancer agents.  
Results: Speakers and panelists explored the utility of information derived from existing and emerging PRO 
measures, focusing on the PRO version of the EĂƚŝŽŶĂůĂŶĐĞƌ/ŶƐƚŝƚƵƚĞ ?ƐCommon Terminology Criteria for 
Adverse Events (PRO-CTCAE ?). Panelists and speakers discussed potential ways to improve the collection, analysis, 
and presentation of PRO data describing symptomatic adverse events in order to support product development 
and better inform regulatory and treatment decisions. Workshop participants concluded the day with a discussion 
of possible approaches to the patient-reported assessment of an investigational ƉƌŽĚƵĐƚ ?Ɛ overall side effect 
burden as a potential clinical trial endpoint.  
Conclusions: FDA reiterated its commitment to collaborate with international product development stakeholders 
to identify rigorous methods to incorporate the patient perspective into the development of cancer therapeutics.  
 
 
 
INTRODUCTION 
The newly formed FDA Oncology Center of Excellence (OCE) has identified patient-focused drug development 
(PFDD) as one of its important initial programs to advance cancer therapeutic development. 1 One of the priority 
areas for the OCE is to foster scientific outreach and investigation into the use of patient-reported outcomes (PRO) 
and other clinical outcome assessments (COA) in cancer clinical trials. When reviewing clinical trials supporting the 
safety and efficacy of cancer therapeutics, the FDA has recently described its perspective on the current 
opportunities and challenges with the use of PRO measures, placing initial focus for product labeling on analysis of 
PRO measures of disease- and treatment-related symptoms and physical function. 2  FDA has reiterated that while 
symptoms and physical function will be the initial focus of FDA analyses for product labeling purposes, other 
aspects of the patient experience may also be important to measure, and all submitted PRO data will be taken into 
account during product review. 3 
Newer products approved for the systemic treatment of cancer have increasingly diverse mechanisms of action 
and are frequently administered orally and on a daily schedule. Unprecedented efficacy seen with targeted and 
immune-based therapies has led to a longer more chronic course of anti-cancer treatment with accompanying 
heterogeneous side effect profiles. These contemporary therapies stand in sharp contrast to the cytotoxic, 
intravenous, fixed-duration regimens that have been the backbone of most cancer therapy for decades. 
Characteristic toxicities observed with cytotoxic therapies are being replaced with an array of different types, 
severities and duration of symptomatic side effects. While the advances seen with these new therapies are 
welcome, prolonged treatment necessitates a closer look at low grade but potentially burdensome symptomatic 
side effects that can decrease quality of life and adversely impact long-term adherence. 4 
The U.S. Food and Drug Administration (FDA) partnered with the Critical Path Institute ?ƐWZKConsortium to 
conduct a public workshop on April 25, 2017 in Bethesda, MD to explore the use of PRO measures to inform 
tolerability in cancer clinical trials. 5  Speakers, panelists and participants represented diverse stakeholder groups, 
including patients, clinicians, clinical investigators, industry representatives and international regulators involved in 
oncology drug development. In this meeting report, we summarize the four sessions of this public workshop and 
identify areas of future research and development.  
Exploring the Concepts of Safety and Tolerability ʹ Incorporating the Patient Voice  
The first session explored the concepts of safety and tolerability from the perspective of patients, international 
regulators, academic clinical trialists and the biopharmaceutical industry. The panel reviewed a common definition 
of safety and tolerability provided in the International Conference for Harmonisation E9 guideline (Figure 1). 6  The 
panel clarified that safety and tolerability are related but distinct from one another. Safety reflects the medical risk 
to the patient, frequently involves clinical judgment, and incorporates the overall adverse event profile of the 
product including both symptomatic and asymptomatic laboratory, radiographic, and clinical events, as well as 
symptomatic side effects. Tolerability reflects the extent to which overt adverse effects ŝŵƉĂĐƚƚŚĞƉĂƚŝĞŶƚ ?Ɛ
willingness to remain on the current treatment dose. Key contributors to tolerability include those effects that are 
symptomatic and bothersome to the patient (as compared to laboratory abnormalities which can commonly go 
unnoticed). The panel generally agreed that whereas the assessment of safety requires clinical judgment relying on 
clinical assessment of the patient, the ability to continue a therapy at its recommended dose (tolerability) could be 
informed by patient assessment of symptomatic side effects. 
Panelists commented that in addition to better communicating ĂĚƌƵŐ ?ƐƐŝĚĞĞĨĨĞĐƚƉƌŽĨŝůĞ, there are other 
potential benefits of using PRO measures to improve the understanding ŽĨĂĚƌƵŐĐĂŶĚŝĚĂƚĞ ?Ɛtolerability. For 
example, improved characterization of tolerability during early phase trials could inform dose selection for later 
phase trials. Moreover, tolerability is the ability to continue to adhere to the prescribed dose and schedule of a 
therapy; therefore any efficacy resultant from drug exposure is reliant to some degree on tolerability. Better 
methods to understand tolerability could inform both safety and efficacy and could be valuable to inform decision 
making for all drug stakeholders. 
Panelists noted that current information informing tolerability (e.g. dose modification and discontinuation and 
CTCAE information on worst grade adverse events) was considered limited. Patient panelists in particular noted 
that simply knowing how many patients were dose reduced or discontinued therapy, while important, does not 
provide information regarding how patients experience treatment and which bothersome symptoms, if any, may 
be impacting those treatment decisions. Consistent with a survey of academic, patient and FDA stakeholders 
reported by Bruner and colleagues7, the panel agreed that assessment of symptomatic adverse events using 
patient-reported measures could be useful.     
Assessment of Safety and Tolerability ʹ Emerging Patient-Reported Methods 
The second session brought together experts from the National Cancer Institute (NCI), industry and academia to 
discuss current developments in the use of patient-reported outcome (PRO) measures to inform tolerability in 
cancer trials. Currently, safety is predominately based on clinician evaluation of adverse events and is documented 
using the Common Terminology Criteria for Adverse Events (CTCAE), a grading system used across all cancer 
clinical trials to ensure consistent severity scoring.8 These clinician-reported outcomes are important to monitor 
the safety of trial participants, and are included in FDA product labeling as descriptive data to represent the overall 
safety of the treatment regimen. CTCAE data includes both symptomatic adverse events (e.g. nausea, fatigue), 
together with laboratory, radiographic, or clinical AEs, and the AE is then interpreted and graded by clinicians using 
the CTCAE criteria. Recognizing that symptomatic adverse events may not be observable and are best quantified 
by the patients themselves, the NCI developed a patient-reported outcome (PRO) version of the CTCAE entitled the 
PRO-d ? ? 9 10 11 
The panel reviewed the development of the PRO-CTCAE measurement system to date, and highlighted the fact 
that it has been adopted for use in more than a dozen countries and has been in multiple academic and 
pharmaceutical industry-sponsored cancer clinical trials. PRO-CTCAE has been publicly available on the NCI-PRO-
CTCAE website since April of 2016. 11  The measurement system is still relatively early in its evolution and there are 
a number of measurement, interpretation, and implementation considerations to be addressed to support further 
adoption in global cancer trials. Several industry panelists discussed their early experience with using the PRO-
CTCAE and provided an update from the multi-stakeholder PRO-CTCAE Industry Working Group on progress made 
to address internal and external barriers to adoption in multinational trials. (Table 1)   Topics discussed included 
translation and cross-cultural adaptation efforts as well as sharing best practices for data-driven methods for item 
selection and the standardized collection, analysis and presentation of data. The panel noted that continuing to 
update item libraries with new symptoms would be important as novel toxicities are encountered during drug 
development. It was generally agreed that systematic assessment of PRO measures informing tolerability could be 
useful for drug development, and that PRO-CTCAE could be one important tool to achieve this trial objective. 
The session concluded with a discussion of how safety and tolerability are currently analyzed and presented in 
most publications and FDA-approved product labeling. Adverse event tables included in product labeling typically 
present the incidence rate and severity of an adverse event observed at any time during the course of the trial. 
While there are benefits to such an approach including simplicity and familiarity to clinicians, such an approach 
does not provide information regarding the trajectory of adverse events or information on their burden to 
patients. As such, there is growing interest in exploring longitudinal approaches to present safety and tolerability 
data. 4  The panel discussed several longitudinal methods that could be used to analyze clinician-reported 
outcomes (CTCAE) or patient-reported outcomes.  Panelists agreed that clinician and patient-reporting of 
symptomatic AEs are complementary, and that PRO measures provide a strategy to directly capture the frequency, 
severity and impact of symptoms directly from patients without interpretation by clinicians. (Table 2). Panelists 
noted that CTCAE remains the standard for grading symptomatic adverse events in cancer clinical trials. However, 
capture of symptomatic adverse events using a PRO measure offers valuable information to improve our precision 
in gauging symptoms that can affect the tolerability of treatment, particularly in contexts where symptomatic 
adverse events are common, tend to be low grade, and when treatment is given over the long term. The session 
concluded with calls to advance our understanding of the longitudinal analysis of symptomatic adverse events 
using PRO measures.  
Analysis and Display of PRO-Based Tolerability Data ʹ Metrics and Paths Forward 
Building from the prior session, the third panel brought together researchers with expertise in data analytics to 
review longitudinal methods to analyze and present PRO data capturing symptomatic adverse events. A simulated 
data set with variables that included PRO-CTCAE was provided to panelists.  Panelists evaluated various 
approaches to data analysis and characterization of missing data. Several different visualization techniques were 
presented that could be used to summarize data, and each had strengths and limitations.  
Analytic and graphical methods explored included stacked bar charts of response over time by treatment arm, 
stacked bar charts of response over time by treatment arm and baseline, heat maps of response over time by 
treatment arm, area under the curve, line graphs depicting the proportion of any level of response at each 
assessment by treatment arm, and latent class trajectory analysis which groups patients into different patterns of 
symptom trajectory ( SůĂƚĞŶƚĐůĂƐƐĞƐ ?). The panel also discussed tabular presentations of the data as a way to 
summarize PRO-based symptomatic adverse event data. For example, rates of each symptomatic adverse event 
across post-baseline assessments  grouped by treatment arm or cumulative incidence across post-baseline PRO 
assessments can be displayed in tables. A revision of a previously proposed method to adjust for baseline scores12 
was also discussed as a way to present the data, which displays only those symptomatic adverse events that 
worsened from an existing baseline score. There was consensus that carefully defining the research objective (e.g. 
describing specific symptoms for those on treatment) and defining the analysis population (e.g. the at-risk 
population who are receiving therapy and offered PRO assessments) is the first step in selecting the appropriate 
analytic strategy.   
The panel identified several key issues to consider when analyzing and describing longitudinal descriptive 
symptomatic adverse event data (Table 3). The session concluded by noting that there was no single analysis or 
representation of data that will address all study aims, but that standard principles and analyses must be 
developed, and a consistent method to summarize longitudinal data graphically that finds the balance between 
the strengths and limitations of the various methods would be useful. Approaches to the analysis of longitudinal 
symptomatic adverse events data continues to be actively investigated.     
From Individual Symptoms to Overall Side Effect Burden 
The final session explored different methods to assess overall symptomatic side effect burden. A more global 
impression of the impact of symptomatic adverse events would be useful for patients, clinicians and from a 
regulatory and drug development standpoint. For instance, if one is assessing 6 different symptomatic side effects, 
it is unclear whether all important side effects were assessed, and what weight patients apply to each side effect 
based on its impact on their daily lives. Hence, a patient-reported global measure of the overall side effect burden 
may be useful that takes into account the perceived overall burden to the patient of all the symptoms of a ĚƌƵŐ ?Ɛ
particular adverse event profile. (Figure 2)  
The panelists discussed several methods and existing tools that could provide a summative measure of overall side 
effect burden. Where scores are available for patient-reported severity of multiple symptomatic adverse events, 
one method would be to add or average the unweighted scores into a total symptom score for the symptomatic 
adverse events assessed. Similar methods have been used in multi-item disease symptom scales for efficacy 
assessment such as the development of a disease symptom measure for myelofibrosis. 13  Summary scores have 
also been used for health-related quality of life tools (HRQL) and their functional domains such as physical 
function. 14,15 Adding or averaging unweighted scores from a set of symptomatic adverse events assessed in a trial 
would provide an overall symptomatic adverse event score, but this method has limitations and care must be 
taken that potentially important side effects are not missed or diluted by the addition of irrelevant symptoms. 
Additionally, different patients may apply different weight to the occurrence of one symptom over another and 
this method does not take this into account. 
  The panel also discussed assessing overall side effect burden using a single question. An example was taken from 
the Functional Assessment of Cancer Therapy- General (FACT-G). 14  The FACT-G GP5 item ? S/ĂŵďŽƚŚĞƌĞĚďǇƐŝĚĞ
ĞĨĨĞĐƚƐŽĨƚƌĞĂƚŵĞŶƚ ? has strengths including simplicity and the ability of individual patients to internally weight 
what was most important to them. Preliminary unpublished exploratory analyses of existing trial data were 
presented during the workshop suggesting that higher levels of self-reported side-effect bother can be associated 
with higher maximum grade CTCAE-reported toxicities and lower utility-based health status scores. The panel 
acknowledged the challenges associated with single item measures of a global concept and more work must be 
done to evaluate the acceptability and responsiveness of a single global item as an endpoint to summarize overall 
side effect burden. 
In addition to exploring the value of a summary measure of side effect bother, the panel also examined the 
potential utility of a summary measure of how side effects interfere with usual and daily activities. The panel 
considered the interference scale from the MD Anderson Symptom Inventory (MDASI). 16  The panel was not 
intended to arrive at consensus on the optimal method to assess overall side effect burden, but rather to begin a 
substantive dialogue. While the MDASI interference scale is not specific to symptomatic adverse events, but rather 
symptoms in general, the importance and utility of such a measure was acknowledged, and panelists noted that 
further study is warranted.  
A PRO measure of overall side effect burden could complement information about the specific profile of 
symptomatic side effects captured using a PRO tool such as PRO-CTCAE, and could be used as key supportive data 
in trial designs that aim to distinguish the profile and consequences of symptomatic adverse events. Such a 
measure could aid in providing a range of side effect burden that could inform various levels of tolerability, 
thereby informing conclusions about the comparative tolerability of two similarly effective agents. In addition to a 
specific PRO measure of overall side effect burden, symptomatic adverse events can affect functioning and health 
related quality of life, and while these more distal concepts are influenced by more than the side effect profile of 
the drug alone, a description of physical function and other aspects of HRQL assessed in the trial can also provide 
complementary information on the overall impact of the side effect profile of a cancer therapy on the patient.   
Conclusion 
The U.S. Food and Drug Administration (FDA) and Critical Path Institute conducted a public workshop exploring the 
use of PRO measures to complement existing clinical safety assessments and inform cancer treatment tolerability. 
This workshop highlighted several areas of opportunity to systematically gather information about symptomatic 
adverse events using PRO measures, and communicate it to patients, clinicians and regulators in interpretable and 
meaningful ways.  The assessment of safety and tolerability is critical at all stages of drug development, and 
tolerability is influenced by overt symptomatic side effects. The use of a PRO measure has been recommended 
when a trial endpoint is a concept that is best known by the patient and can be validly and reliably captured by 
self-report. This workshop supports systematic assessment of patient-reported symptomatic adverse events using 
an item library such as the PRO-CTCAE to provide complementary data to existing measures of safety. Work is 
underway to address barriers to wider adoption of the PRO-CTCAE and other measures of symptomatic adverse 
events in international clinical trials. Sustained international collaboration on trial design, analysis methods and 
measurement of overall side effect burden is ongoing. 
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TABLES: 
Table 1: Update from the PRO-CTCAE Industry Working Group 
Roadmap of PRO-CTCAE Industry Working Group Activities 
 Task Completion Time Frame 
Completed Activities  
Licensing Process ƐƐĞƐƐE/ ?ƐŽŶ-line 
registration platform 
launched in April 2016 to 
evaluate whether it addresses 
current access barriers 
WG pleased with functionality and 
convenience of on-line process 
Item Selection-  
Early Stage Trials 
Develop consensus 
recommendations on item 
selection approaches for 
early-stage cancer trials 
Item selection process for early stage 
studies was reviewed by WG; ISOQOL 2016 
abstract on general approach for early 
phase trials was published (18)  
Ongoing Activities 
Item Selection- 
Registration Trials 
Develop consensus 
recommendations on item 
selection approaches for 
registration trials 
Item selection process for late stage 
studies was reviewed by WG in Feb 2017; 
Ongoing  work underway to create 
objective methods for unbiased item 
selection in registration trials  
Translation and Linguistic 
Validation 
Develop proposal for 
translation and linguistic 
validation of PRO-CTCAE into 
more languages 
Industry-sponsored collaboration between 
NCI and Corporate Translations Inc. to 
translate and linguistically validate PRO-
CTCAE in 12 additional languages. This 
work  is anticipated to be completed by 
December 2017 
Data Collection Standards Develop consensus 
recommendations on 
approaches to enabling, 
coding, + analyzing patient 
write-in responses 
Initiated work in Sept 2016 and discussed 
approaches with WG in Sept 2016; on-
going review of proposal 
Data Analysis and 
Presentation Standards 
Develop consensus 
recommendations on data 
scoring/analysis, and data 
presentation formats 
Initiated work in August 2016; on-going 
development and review of proposals 
Remaining Activities 
Data Collection Standards Develop consensus 
recommendations on: 
- Clinical monitoring of PRO- 
CTCAE data 
- Consistency of platforms for 
Short-term activity for 2017.  
Discussed clinical monitoring of PRO-
CTCAE data with FDA and NCI in Q1. 
NCI and FDA are working with the 
Clinical Data Interchange Standards 
electronic administration Consortium (CDISC) to develop PRO-
CTCAE data standards 
Data Analysis Standards Develop consensus 
recommendations for 
standardized data 
scoring/analysis methods 
Long-term activity; will be informed by 
data gathered from utilizing instrument 
on a wider scale 
Data Presentation 
Standards 
Share best practices for 
presenting data in submissions, 
manuscripts, drug label 
Short/long-term activity; development 
of data presentation examples underway 
 
 
 
 
 
Table 2: Complementary information on drug safety and tolerability provided by conventional CTCAE reporting and 
longitudinal analysis of both clinician- and patient-reported data sources. 
 
* PRO-CTCAE does include the option for a patient to  SǁƌŝƚĞ-ŝŶ ?a symptom they are experiencing that may allow 
for screening of unexpected symptomatic adverse events (AEs) from the patient perspective. 10,11 
Note: Conventional CTCAE clinician reported adverse events will remain the core of safety monitoring and 
reporting in cancer trials. Longitudinal analysis and use of PRO measures such as PRO-CTCAE can add important 
complementary information that may better inform tolerability. 
  
 
 
 
 
 
 
 
 
Table 3: Considerations for analytic and visualization methods to describe longitudinal symptomatic adverse 
events assessed by PRO measures 
Research objective Clearly identify the research question to address 
x This workshop focused on describing symptomatic adverse events 
over time for patients undergoing anti-cancer therapy 
Analysis population Define the analysis population based on the research question 
x For this analysis we selected those patients who are on study and 
on treatmenƚ ?dŚĞWZKƐǇŵƉƚŽŵĂƚŝĐĂĚǀĞƌƐĞĞǀĞŶƚ SĂƚ-ƌŝƐŬ ?
population.  
x  
Completion rate (DataQuality) Characterize the completion rate for those patients who were on study and 
scheduled to complete a PRO assessment. 
x Informs the quality of study conduct, study personnel training, and 
importance placed on data collection 
x Lower completion rates and missing observations can limit the 
interpretability, reproducibility, or generalizability of study results.  
Missing data Address uncertainty due to missing data 
x Collect specific reasons for missing observations 
Account for baseline Taking baseline into consideration provides additional information about 
safety and tolerability, and may inform AE attribution.  
Data visualization All analytic methods and visualizations will have strengths and limitations. 
No one method will satisfy all objectives. 
x A standard visualization is needed that leverages the benefits of 
longitudinal systematically assessed PRO data, takes baseline 
symptoms into account, and is interpretable to treating physicians 
and patients 
x Visualizations should have the intended audience in mind, and 
separate visualizations for clinicians and patients may be needed 
Note: Identification of standard analysis and visualization methods for PRO data is an area of active regulatory 
science and international collaboration. 17 
 
 
 
